lovotibeglogene autotemcel

Lovotibeglogene autotemcel is a gene therapy medication used to treat sickle cell disease in patients 12 years and older with a history of vaso-occlusive events. It's marketed under the brand name Lyfgenia and was approved by the FDA in December 2023. ## Mechanism of Action Lovotibeglogene autotemcel is an autologous cellular immunotherapy prepared using the patient's own blood stem cells. The therapy works by genetically modifying the patient's CD34+ hematopoietic stem cells (HSCs) with a lentiviral vector (BB305) that encodes a modified form of the β-globin gene called β-A-T87Q-globin[1][2][5]. After infusion, these modified stem cells engraft in the bone marrow and differentiate to produce red blood cells containing biologically active β-A-T87Q-globin. This modified globin combines with α-globin to produce functional hemoglobin (HbA T87Q)[2]. The modified hemoglobin has similar oxygen-binding properties to normal hemoglobin but reduces intracellular and total hemoglobin S (HbS) levels and inhibits the polymerization of HbS, thereby limiting the sickling of red blood cells[2]. ## Administration Process The treatment involves several steps: 1. Collection of the patient's blood stem cells through mobilization and apheresis 2. Genetic modification of these cells in a laboratory 3. Administration of chemotherapy (myeloablative conditioning) to prepare the body 4. Infusion of the modified cells back into the patient The entire process from cell collection to treatment can take approximately 10-15 weeks[1]. Patients typically need to stay in the hospital for 3-6 weeks after receiving the treatment for monitoring[1]. ## Side Effects Common side effects include: - Stomatitis (mouth sores) - Low levels of platelets, white blood cells, and red blood cells - Febrile neutropenia (fever with low white blood cell count) - Thrombocytopenia - Neutropenia - Anemia - Leukopenia[5][6] ## Important Safety Information The FDA has noted serious safety concerns, including: - Delayed platelet engraftment - Neutrophil engraftment failure - Risk of insertional oncogenesis (potential development of blood cancers) - Hypersensitivity reactions[6] - Hematological malignancy (cancers of the blood)[1] Lovotibeglogene autotemcel represents a significant advancement in the treatment of sickle cell disease, offering a one-time therapy that addresses the underlying genetic cause of the condition rather than just managing symptoms.

Brand names

Lyfgenia

Other names

LentiGlobinLentiGlobin for SCD